소외열대질환 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Neglected Tropical Diseases Market size is expected to reach USD 6.90 Billion in 2034 from USD 4.54 Billion (2025) growing at a CAGR of 4.77% during 2026-2034.

The global neglected tropical diseases market has gained attention due to increasing global health initiatives aimed at combating infectious diseases in low-income regions. Governments, non-governmental organizations, and international health agencies are investing in research, treatment, and prevention programs. The burden of diseases such as dengue, leishmaniasis, and Chagas disease continues to drive demand for effective therapeutics and diagnostics. Emerging funding mechanisms and partnerships have strengthened market development.

Key drivers include rising disease awareness, expanded healthcare access in endemic regions, and support from global health organizations. Public-private partnerships have accelerated drug development and distribution. Advances in diagnostic technologies and vaccine research have further enhanced disease management strategies. Additionally, philanthropic funding and policy frameworks are encouraging pharmaceutical companies to participate in neglected disease programs.

Future prospects appear positive as innovation in biologics, vaccines, and targeted therapies continues. Strengthening healthcare infrastructure in developing regions will support wider treatment access. Increased collaboration among research institutions, governments, and pharmaceutical firms will drive pipeline development. As global focus on equitable healthcare intensifies, the neglected tropical diseases market is expected to witness sustained growth and long-term investment opportunities.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disease Type

• Mediterranean Fever
• Ebola Virus Infection
• Chagas Disease
• Zika Virus Infection
• Chikungunya
• Others

By Treatment

• Drugs
• Vaccine

By Route of Administration

• Oral
• Injectable

By End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

COMPANIES PROFILED

• Emergent BioSolutions Inc, Moderna, Valneva SE, Johnson Johnson Services, DAIICHI SANKYO COMPANY, LIMITED, Insud Pharma Group, Humanigen Inc, Savant HWP Inc, Bayer AG, Eisai Co Ltd, Oblita Therapeutics, GlaxoSmithKline plc, Themis Bioscience GmbH, Novartis AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease Type
• 4.2. Mediterranean Fever Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Ebola Virus Infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Chagas Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Zika Virus Infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Chikungunya Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY TREATMENT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment
• 5.2. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL NEGLECTED TROPICAL DISEASES MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Disease Type
  • 9.2.2 By Treatment
  • 9.2.3 By Route Of Administration
  • 9.2.4 By End User
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Disease Type
  • 9.3.2 By Treatment
  • 9.3.3 By Route Of Administration
  • 9.3.4 By End User
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Disease Type
  • 9.4.2 By Treatment
  • 9.4.3 By Route Of Administration
  • 9.4.4 By End User
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Disease Type
  • 9.5.2 By Treatment
  • 9.5.3 By Route Of Administration
  • 9.5.4 By End User
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Disease Type
  • 9.6.2 By Treatment
  • 9.6.3 By Route Of Administration
  • 9.6.4 By End User
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL NEGLECTED TROPICAL DISEASES INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Emergent BioSolutions Inc
  • 11.2.2 Moderna
  • 11.2.3 Valneva SE
  • 11.2.4 Johnson & Johnson Services
  • 11.2.5 DAIICHI SANKYO COMPANY
  • 11.2.6 LIMITED
  • 11.2.7 Insud Pharma Group
  • 11.2.8 Humanigen Inc
  • 11.2.9 Savant HWP Inc
  • 11.2.10 Bayer AG
  • 11.2.11 Eisai Co. Ltd
  • 11.2.12 Oblita Therapeutics
  • 11.2.13 GlaxoSmithKline Plc
  • 11.2.14 Themis Bioscience GmbH
  • 11.2.15 Novartis AG